Search | Clinical Trials Finder

Conditions: Hemophilia A
Interventions: recombinant porcine coagulation factor VIII (OBI-1); Drug
Lead sponsor: Octagen Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Blue Bell, Pennsylvania

Conditions: Hemophilia A
Interventions: GreenGene™ F; Biological
Lead sponsor: Green Cross Corporation; Industry
Eligibility: Not listed
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Little Rock, Arkansas • New Hyde Park, New York

Conditions: Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
Interventions: coagulation factor VIIa [recombinant]-jncw; Drug
Lead sponsor: American Thrombosis and Hemostasis Network; Network
Eligibility: 12 Years to 100 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 21
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 17 more

Conditions: Hemophilia A With Inhibitor, Hemophilia A With Anti Factor VIII
Interventions: Valoctocogene roxaparvovec; Biological
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hemophilia A
Interventions: Recombinant coagulation factor (rFVIIIFc); Biological
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Healthy Participants, Hemophilia A, Hemophilia B, Factor VII Deficiency
Interventions: SR604, Placebo; Drug
Lead sponsor: Equilibra Bioscience LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 9
States / cities: Glendale, California • Los Angeles, California • Chicago, Illinois + 6 more

Conditions: HIV Infections, Hemophilia A
Interventions: Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1989
U.S. locations: 2
States / cities: Buffalo, New York • Rochester, New York

Conditions: Haemophilia A With or Without Inhibitors
Interventions: Mim8; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 1 Year to 11 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 9
States / cities: Los Angeles, California • Aurora, Colorado • Tampa, Florida + 6 more

Conditions: Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions: activated recombinant human factor VII, factor IX, factor VIII; Drug · Other
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 5 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 14
States / cities: Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 9 more

Conditions: Severe Hemophilia A, Moderate Hemophilia A
Interventions: Emicizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years to 69 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Los Angeles, California • Miami, Florida • Oklahoma City, Oklahoma

Conditions: Significant Bleeding Risk
Interventions: Octaplex, Beriplex P/N (Kcentra); Drug
Lead sponsor: Octapharma; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 22
States / cities: Aurora, Colorado • New Haven, Connecticut • Miami, Florida + 14 more

Conditions: Hemophilia B
Interventions: FLT180a; Biological
Lead sponsor: University College, London; Other
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Hemophilia A
Interventions: Blood sample collection; Procedure
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 18 Years and older
Enrollment: 186 participants
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hemophilia
Interventions: SureSource Engage application; Device
Lead sponsor: Healthcare Innovation Technology Lab; Industry
Eligibility: 18 Years to 63 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:; Drug
Lead sponsor: Duke University; Other
Eligibility: 0 Years to 20 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 49
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more

Conditions: Blood Coagulation Disorder, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, Hemophilia A, Genetic Diseases, Inborn, Genetic Diseases, X-Linked, Hematologic Diseases, Hemorrhagic Disorders, Factor VIII Deficiency
Interventions: Standard of Care FVIII Replacement therapy; Drug
Lead sponsor: Spark Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 25 participants
Timeline: 2019 – 2023
U.S. locations: 6
States / cities: San Francisco, California • Gainesville, Florida • Atlanta, Georgia + 3 more

Conditions: Hemophilia A
Interventions: SIG-001; Combination Product
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Indianapolis, Indiana • Boston, Massachusetts • Seattle, Washington

Conditions: Hemophilia B, Hemophilia A
Interventions: Standard of Care FIX Replacement therapy, Standard of Care FVIII Replacement therapy; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 64 Years · Male only
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 13
States / cities: Palo Alto, California • San Francisco, California • Stanford, California + 7 more

Conditions: Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions: eptacog alfa (activated); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 5 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Hemophilia A
Interventions: BAX855; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: Up to 75 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 21
States / cities: Phoenix, Arizona • Aurora, Colorado • Gainesville, Florida + 18 more

Conditions: Hemophilia B
Interventions: PF-06838435/ fidanacogene elaparvovec; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2031
U.S. locations: 17
States / cities: San Francisco, California • Aurora, Colorado • Indianapolis, Indiana + 3 more

Conditions: Hemophilia A, Hemophilia B
Interventions: Hemophilia B standard half-life, Hemophilia B extended half-life, Hemophilia A standard half-life, Hemophilia A extended half-life; Drug
Lead sponsor: Pfizer; Industry
Eligibility: Not listed
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Gainesville, Florida • Las Vegas, Nevada • Fort Worth, Texas

Conditions: Hemophilia A, Hemophilia B
Interventions: PF-06741086; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years to 74 Years · Male only
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 4
States / cities: Tampa, Florida • Iowa City, Iowa • New Hyde Park, New York + 1 more

Conditions: Acquired Hemophilia A
Interventions: OBI-1; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 8
States / cities: Indianapolis, Indiana • New Orleans, Louisiana • Bethesda, Maryland + 4 more

Search by objective public record fields.

Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII

Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemophilia A

SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors

Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors

Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)

Safety and Effectiveness of Azidothymidine (AZT) in HIV-Positive Patients With Hemophilia

A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors

Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery

A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis

Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.

A Factor IX Gene Therapy Study (FIX-GT)

A Study to Evaluate Seroprevalence and Seroconversion of Antibodies to Adeno-Associated Virus (AAV) in Patients With Hemophilia A

Hemophilia Mobile App Usability Pilot

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants

Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A

A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)

A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors

BAX 855 Continuation

A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B

Understanding Hemophilia A and B Drug Dosage Administration Patterns

Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A